Abbott's Biosimilar Push to Help Sustain EPD Growth Momentum

Abbott’s Established Pharmaceuticals Division grew sales 9% in Q1 2026, with Key Emerging Markets up 9.4% ex-FX and Other Emerging Markets up 7.9%, indicating continued broad-based momentum. Management remains confident in sustaining growth, supported by biosimilars, local branded generics and ongoing licensing/launch activity across emerging markets. The article is also constructive on Abbott’s valuation, noting the stock trades at 15.59x forward P/E versus a 22.56x historical median.

Analysis

ABT’s EPD resilience is less about a single strong quarter and more about a structurally higher-quality growth engine inside a slower-growth healthcare conglomerate. The important second-order effect is that emerging-market branded generics and biosimilars are becoming a defensive growth vector at a time when developed-market medtech/pharma multiples are being compressed by rate sensitivity and policy noise. If management can keep the launch cadence intact, the market may start re-rating EPD closer to a specialty-platform asset than a legacy generics bucket.

The near-term catalyst is not just revenue growth, but operating leverage from localization and licensing: the model should scale without proportionate capex, which means incremental margin could expand faster than consensus expects over the next 2-4 quarters. The key risk is FX—headline growth can look durable while underlying dollar earnings are flattened by EM currency depreciation, especially if LATAM volatility persists. A second risk is regulatory timing: biosimilar approvals in emerging markets often slip, and the market is likely underestimating the lag between partnership signing and meaningful P&L contribution.

The broader competitive implication is that capital-efficient EM distribution plus biosimilar access can pressure smaller regional generics players more than global innovators. In contrast, BSX’s and QGEN’s developments are longer-dated and more optionality-driven, but they also reinforce that healthcare capital is rotating toward platform assets with multi-year data/launch runways rather than pure single-product stories. The contrarian view is that ABT may be too cheap if investors are over-weighting macro/FX and under-weighting the persistence of EPD’s mix shift; however, if the core U.S. franchises remain slow, the stock can stay value-trapped until EPD becomes visibly larger in the earnings mix.

Key Decisions for Investors

• Add to ABT on weakness over the next 1-2 weeks; target a 6-12 month horizon where EPD mix and biosimilar launches can drive multiple expansion from depressed levels. Risk/reward favors a gradual long because the stock is already priced for pessimism, but FX can delay the rerate.
• Pair trade: long ABT / short a basket of slower-growth healthcare defensives with higher rate sensitivity over a 3-6 month window. The thesis is that ABT’s self-help and EM growth are more durable than valuation implies, while peers with weaker organic growth remain multiple-vulnerable.
• Use BSX strength tactically rather than structurally: trim into any post-trial rally if the market prices in near-term commercialization too aggressively. The MiRus option is interesting but milestone-heavy, so upside is longer-dated and execution-dependent.
• For QGEN, treat the NVIDIA collaboration as a sentiment catalyst, not a near-term earnings driver. Consider a short-dated call spread only if the stock has not already re-rated on AI-bioinformatics enthusiasm; otherwise the risk/reward is too dependent on future platform adoption.
• Hedge ABT with an FX-sensitive emerging-market healthcare basket if you want to isolate operating execution from currency noise. This preserves exposure to the EPD growth story while limiting downside if dollar strength resurges.